caa a22 4500 463208137 CHVBK 20180405153132.0 cr unu---uuuuu 170326e20070201xx s 000 0 eng 10.1007/s10863-006-9058-6 doi (NATIONALLICENCE)springer-10.1007/s10863-006-9058-6 Arsenic trioxide and neuroblastoma cytotoxicity [Elektronische Daten] [Helen Pettersson, Jenny Karlsson, Alexander Pietras, Ingrid Øra, Sven Påhlman] The majority of aggressive forms of the childhood tumor neuroblastoma can with current treatment protocols not be cured and possess a major challenge in pediatric oncology. After initial rounds of chemotherapy, surgery and irradiation, which in most cases result in tumor regression, these aggressive neuroblastomas relapse and frequently develop drug resistance. As approximately 50% of the children with neuroblastoma have an aggressive form, there is a compelling demand for new treatment strategies. Arsenic trioxide has the capacity to kill multidrug-resistant neuro-blastoma cells in vitro and in vivo and the drug is currently being evaluated in clinical trials. In this report we discuss the background to the use of arsenic trioxide in cancer therapy and the currently known mechanisms by which arsenic trioxide kills human neuroblastoma cells. Springer Science+Business Media, LLC, 2007 Neuroblastoma nationallicence Arsenic trioxide nationallicence Cell death nationallicence Bax nationallicence APL nationallicence Pettersson Helen Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden aut Karlsson Jenny Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden aut Pietras Alexander Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden aut Øra Ingrid Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden aut Påhlman Sven Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden aut Journal of Bioenergetics and Biomembranes Kluwer Academic Publishers-Plenum Publishers; http://www.springer-ny.com 39/1(2007-02-01), 35-41 0145-479X 39:1<35 2007 39 10863 https://doi.org/10.1007/s10863-006-9058-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10863-006-9058-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Pettersson Helen Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden aut NATIONALLICENCE 700 1- Karlsson Jenny Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden aut NATIONALLICENCE 700 1- Pietras Alexander Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden aut NATIONALLICENCE 700 1- Øra Ingrid Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden aut NATIONALLICENCE 700 1- Påhlman Sven Department of Laboratory Medicine, Division of Molecular Medicine, Lund University, University Hospital MAS, Malmö, Sweden aut NATIONALLICENCE 773 0- Journal of Bioenergetics and Biomembranes Kluwer Academic Publishers-Plenum Publishers; http://www.springer-ny.com 39/1(2007-02-01), 35-41 0145-479X 39:1<35 2007 39 10863 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer